Skip to content

Determining the accuracy of non-invasive biomarkers for detecting pre-cancerous colorectal neoplasia

Determining the accuracy of non-invasive biomarkers for detecting pre-cancerous colorectal neoplasia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12620000668909
Acronym
CYSP20
Enrollment
2230
Registered
2020-06-11
Start date
2020-06-24
Completion date
2026-04-27
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to develop new and simple ways to screen which patients with bowel symptoms, inflammation, or anaemia will need a colonoscopy using a novel biomarker test. These results can help reduce the need for colonoscopy, and prioritising it for those that need it most. Who is it for? You may be eligible for this study if you are an adult who is booked for a colonoscopy at participating hospitals for any indication. Study details: After completing a consent form, participants may be provided a faecal immunochemical test (FIT) kit and questionnaire for completion. Participants may also be met before their colonoscopy to have a short medical history interview & blood sample taken. Optionally, tissue samples may also be requested from the colonoscopy, Samples will be analysed for biomarkers which might indicate that there is inflammation, cancer, or polyp in the bowel. Biomarker results will be compared to colonoscopy findings. Sometimes there are long waiting lists for colonoscopies. The development of novel biomarker tests will help guide doctors in determining which patients need colonoscopy.

Interventions

This study will discover and develop novel blood & stool biomarkers. Biomarkers will be evaluated for both their ability and acceptability to detect inflammation, adenomas, and cancer in patients with gastrointestinal symptoms. The development of new screening tests will help guide doctors in determining which symptomatic patients need colonoscopy. People undergoing colonoscopy for any reason, such as experiencing gastrointestinal symptoms, having had a microscopic rectal bleed (by indication of

This study will discover and develop novel blood & stool biomarkers. Biomarkers will be evaluated for both their ability and acceptability to detect inflammation, adenomas, and cancer in patients with gastrointestinal symptoms. The development of new screening tests will help guide doctors in determining which symptomatic patients need colonoscopy. People undergoing colonoscopy for any reason, such as experiencing gastrointestinal symptoms, having had a microscopic rectal bleed (by indication of a faecal occult blood test), inflammatory bowel disease, bowel cancer surveillance etc., will be pre-screened for eligibility. Patients undergoing colonoscopies at the Southern Adelaide Local Health Network (Flinders Medical Centre, Noarlunga Health Service), Central Adelaide Local Health Network (Royal Adelaide Hospital, The Queen Elizabeth Hospital) and Private Hospitals (Tennyson Centre Day Hospital) will be invited. A text message invite will be sent to eligible individuals, and if they agree to further contact, a study pack will be sent to them. The study pack will contain an invitation letter, participant information and consent form, health questionnaire and two faecal immunochemical test (FIT) kits or a FIT kit and a new rapid antigen bowel screening test. Participants may be met before their colonoscopy appointment by a member of the research team to have a short medical history interview & a blood sample taken. Participants may also provide a stool sample prior to their colonoscopy. Samples of tissue (biopsies) may be requested from colonoscopy by opt-in consent. Left-over tissue samples collected from participants as part of clinical care may also be accessed. Candidate biomarkers (which indicate presence of pathological change in the bowel) will be identified from molecular analyses on tissue samples. Stool and blood samples will be subsequently analysed to determine the lead biomarkers, with results compared to the findings at colonoscopy.

Sponsors

Flinders University of South Australia
Lead SponsorUniversity

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

People booked for a colonoscopy at our approved study sites who are: - Aged 18 years or over, and -Willing and able to provide a blood, stool, and/or tissue sample

Exclusion criteria

None

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026